The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price
Value in Health · 2023
DOI: 10.1016/j.jval.2023.01.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2023. Verfasst von Deirdre Mladsi und 5 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Research Triangle Park, NC, USA. Electronic address: dmladsi@rti.org. Hauptthemen laut MEDLINE: Health Care Costs, Cost-Effectiveness Analysis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: RTI International, Pfizer.
Abstract (Originalsprache)
OBJECTIVES: The zero-price conundrum occurs when a clinically effective drug can justify no greater than a price of zero based on cost-effectiveness criteria from a health system perspective. This is relevant for health systems that require evidence of cost-effectiveness, in addition to safety and efficacy for drug approval and other analyses that may shape drug coverage policies, such as budget impact and comparative effectiveness. This study aimed to clarify and explore the zero-price conundrum to provide a resource in the development of practical and methodological solutions. METHODS: We specified equations representing previously identified zero-price scenarios and used them to elucidate factors contributing to the zero-price conundrum and explore relationships between them. We present real-world considerations and discuss solutions from the literature. RESULTS: The analyses demonstrated that a primary cause of the zero-price problem for a new drug that increases quality-adjusted survival pertains to healthcare costs beyond the influence of the new drug, specifically, disease background costs, costs of existing drugs used in a combination regimen, and costs of future health interventions patients may become eligible to receive. Pragmatic solutions have been to exclude such costs from cost-effectiveness analyses. Proposed modifications to cost-effectiveness analysis include assessing each drug in a combination regimen based on its relative contribution to improved health. CONCLUSIONS: The zero-price dilemma may arise more frequently as the number of drugs in high-cost disease areas continues to grow. As cost-effectiveness methods evolve, there is the opportunity to develop robust solutions that can be applied consistently.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- RTI Health Solutions, Research Triangle Park, NC, USA. Electronic address: dmladsi@rti.org.
- RTI Health Solutions, Research Triangle Park, NC, USA.
- RTI Health Solutions, Research Triangle Park, NC, USA; AESARA, Chapel Hill, NC.
- Pfizer R&D UK Ltd, Sandwich, Kent, UK.
- AESARA, Chapel Hill, NC; KNG Health Consulting, LLC, North Bethesda, MD.
- AESARA, Chapel Hill, NC; SpringWorks Therapeutics, Durham, NC.
Förderung
- RTI International
- Pfizer
Zitieren
APA
Mladsi, D., Barnett, C. L., Mader, G., Russell-Smith, T. A., Unuigbe, A., & Bell, T. (2023). The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price. Value in Health. https://doi.org/10.1016/j.jval.2023.01.004
Vancouver
Mladsi D, Barnett CL, Mader G, Russell-Smith TA, Unuigbe A, Bell T. The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price. Value in Health. 2023. doi:10.1016/j.jval.2023.01.004
BibTeX
@article{Mladsi2023,
author = {Mladsi, Deirdre and Barnett, Christine L and Mader, Gregory and Russell-Smith, T Alexander and Unuigbe, Aig and Bell, Tim},
title = {The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price},
journal = {Value in Health},
year = {2023},
doi = {10.1016/j.jval.2023.01.004}
}
EUVIMED